Skip to main content

Daniel Kelly Benjamin, MD, PhD

Kiser-Arena Distinguished Professor of Pediatrics
Professor of Pediatrics
Member in the Duke Clinical Research Institute
Campus mail: 7044 Duke Clinical Research Institute, 2400 Pratt St, Durham, NC 27710
Phone: (919) 668-7081

Dr. Danny Benjamin is the Principal Investigator and Chair of the National Institute of Child Health and Human Development’s Pediatric Trials Network. The Network is responsible for designing and leading clinical trials of off-patent medicines in children of all ages across all therapeutic areas. The team has established, or is actively studying, the correct dosing and safety of more than 50 of the most commonly used medicines in children. Each of these trials is conducted under an investigational new drug (IND) application with guidance from the Food and Drug Administration for labeling.

Signature programs of the Network include clinical trials in premature, term infants and most recently, obese children. Over the past 10 years, Dr. Benjamin’s group has enrolled more premature infants, at more sites, in more clinical trials of off-patent anti-infectives under an IND than all other academic medical centers, pharmaceutical companies, and government agencies in the world, combined.

Dr. Benjamin is recognized by the National Institutes of Health as a premiere mentor and educator. His research program serves as a platform to train students and early career investigators. Dr. Benjamin’s group has a clinical research summer program for high school and college students targeting under-represented minority students, and he is the primary mentor for medical students, residents, subspecialty fellows (including two T32 programs sponsored by NIH for which he is PI), and multiple junior faculty.

Dr. Benjamin has published over 250 works with up to 7000 citations. 

Education and Training

  • Fellow, Pediatric Infectious Diseases, Pediatrics, Duke University, 1998 - 2001
  • Resident, Pediatrics, Children's Hospital, 1995 - 1998
  • Ph.D., University of North Carolina at Chapel Hill, 2003
  • M.P.H., University of North Carolina at Chapel Hill, 2001
  • M.D., University of Virginia, 1995

Selected Grants and Awards

Publications

Zimmerman, K., and D. K. Benjamin. “Necrotizing Enterocolitis.” In Principles and Practice of Pediatric Infectious Diseases, 394-397.e2, 2018. https://doi.org/10.1016/B978-0-323-40181-4.00058-X.

Full Text

Ward, Robert M., Daniel K. Benjamin, Jonathan M. Davis, Richard L. Gorman, Ralph Kauffman, Gregory L. Kearns, Mary Dianne Murphy, and Catherine M. T. Sherwin. “The Need for Pediatric Drug Development.” J Pediatr 192 (January 2018): 13–21. https://doi.org/10.1016/j.jpeds.2017.08.011.

Full Text

Hwang, Michael F., Ryan J. Beechinor, Kelly C. Wade, Daniel K. Benjamin, P Brian Smith, Christoph P. Hornik, Edmund V. Capparelli, et al. “External Evaluation of Two Fluconazole Infant Population Pharmacokinetic Models.” Antimicrob Agents Chemother 61, no. 12 (December 2017). https://doi.org/10.1128/AAC.01352-17.

Full Text

Watt, Kevin M., Michael Cohen-Wolkowiez, Duane C. Williams, Desiree K. Bonadonna, Ira M. Cheifetz, Dhiren Thakker, Daniel K. Benjamin, and Kim L. R. Brouwer. “Antifungal Extraction by the Extracorporeal Membrane Oxygenation Circuit.” J Extra Corpor Technol 49, no. 3 (September 2017): 150–59.

Scholars@Duke

Gonzalez, Daniel, James M. Chamberlain, Jeffrey T. Guptill, Michael Cohen-Wolkowiez, Barrie Harper, Jian Zhao, Edmund V. Capparelli, and Edmund V. Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. “Population Pharmacokinetics and Exploratory Pharmacodynamics of Lorazepam in Pediatric Status Epilepticus.” Clin Pharmacokinet 56, no. 8 (August 2017): 941–51. https://doi.org/10.1007/s40262-016-0486-0.

Full Text

Wynn, James L., Matthew S. Kelly, Daniel K. Benjamin, Reese H. Clark, Rachel Greenberg, and P Brian Smith. “Timing of Multiorgan Dysfunction among Hospitalized Infants with Fatal Fulminant Sepsis.” Am J Perinatol 34, no. 7 (June 2017): 633–39. https://doi.org/10.1055/s-0036-1597130.

Full Text

Ward, Robert M., Daniel Benjamin, Jeffrey S. Barrett, Karel Allegaert, Ronald Portman, Jonathan M. Davis, and Mark A. Turner. “Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates.” In Pediatr Res, 81:692–711, 2017. https://doi.org/10.1038/pr.2016.221.

Full Text

Lee, Jin A., Brooke Sauer, William Tuminski, Jiyu Cheong, John Fitz-Henley, Megan Mayers, Chidera Ezuma-Igwe, et al. “Effectiveness of Granulocyte Colony-Stimulating Factor in Hospitalized Infants with Neutropenia.” Am J Perinatol 34, no. 5 (April 2017): 458–64. https://doi.org/10.1055/s-0036-1593349.

Full Text

Smith, Michael J., Daniel Gonzalez, Jennifer L. Goldman, Ram Yogev, Janice E. Sullivan, Michael D. Reed, Ravinder Anand, et al. “Pharmacokinetics of Clindamycin in Obese and Nonobese Children.” Antimicrob Agents Chemother 61, no. 4 (April 2017). https://doi.org/10.1128/AAC.02014-16.

Full Text

Ericson, Jessica E., Martyn Gostelow, Julie Autmizguine, Christoph P. Hornik, Reese H. Clark, Daniel K. Benjamin, P Brian Smith, and P Brian Pediatric Trials Network Executive Committee and Investigators. “Safety of High-dose Acyclovir in Infants With Suspected and Confirmed Neonatal Herpes Simplex Virus Infections.” Pediatr Infect Dis J 36, no. 4 (April 2017): 369–73. https://doi.org/10.1097/INF.0000000000001451.

Full Text

Pages